Browsing Tag
CD3
1 post
Therapeutic potential of CD20 x CD3 bispecific antibodies
On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma…
Unraveling the Tapestry of Science: Dive into Scientific Exploration.